Effects of Androgen Treatment on Growth in Patients with 5-Alpha-Reductase Type 2 Deficiency

June 2023 in “ Journal of personalized medicine ”

Hae In Lee, Sujin Kim, Sang-woon Kim, Myeongseob Lee, Kyungchul Song, Jin‐Suck Suh, Yong Seung Lee, Hyun Wook Chae, Ho-Seong Kim, Sangwon Han, Ahreum Kwon

androgen treatment 5-α-reductase type 2 deficiency dihydrotestosterone DHT testosterone enanthate TE bone age BA height standard deviation scores SDS 5αRD2 height SDS

Studysummary This study found that dihydrotestosterone treatment may be more beneficial for height in children with 5-α-reductase type 2 deficiency compared to testosterone enanthate, especially in the prepubertal period.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study followed 19 patients with 5-α-reductase type 2 deficiency (5αRD2) for an average of 10.6 years, 12 of whom received androgen treatment. The results showed that dihydrotestosterone (DHT) treatment did not increase bone age (BA) or height standard deviation scores (SDS) relative to BA, while testosterone enanthate (TE) treatment resulted in BA advancement and decreased height SDS relative to BA, especially in the prepubertal period. The study concluded that DHT treatment is more favorable for height than TE treatment in patients with 5αRD2, particularly during the prepubertal period. Therefore, age and the type of androgen used should be carefully considered to minimize the risk of height reduction in these patient groups.

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

4 / 4 results

research Androgen Treatment in Adolescent Males With Hypogonadism

19 citations , May 2020 in “American journal of men's health”

This review discusses androgen therapy in adolescents, detailing current practices and noting the limited use of commercially available testosterone or dihydrotestosterone formulations; no new results are reported.

research Effects of Pre- and Post-Pubertal Dihydrotestosterone Treatment on Penile Length in 5α-Reductase Type 2 Deficiency

13 citations , January 2019 in “Endocrine journal”

This study found that transdermal DHT treatment increased penile length in boys with 5α-reductase type 2 deficiency, but post-pubertal growth was limited and carried potential prostate complications.

research 5-Alpha-Reductase Type 2 Deficiency: Is There a Genotype-Phenotype Correlation? A Review

39 citations , April 2018 in “Hormones”

This review suggests that most mutations in the SRD5A2 gene show no clear genotype-phenotype correlation in 5-α-Reductase deficiency, although mutation location affects severity.

research Safety Aspects of Androgen Treatment with 5α-Dihydrotestosterone

16 citations , October 2007 in “Andrologia”

This study suggests that DHT may have a less potent effect on the prostate compared to testosterone while maintaining safety and similar effects on erythropoiesis and lipids.